Sanofi and Teva Pharmaceutical Industries announced positive Phase IIb results for duvakitug, a monoclonal antibody targeting TL1A, in a long-term maintenance study for patients with ulcerative colitis and Crohn's disease. The RELIEVE UCCD LTE trial evaluated the drug's durability in patients who had demonstrated initial clinical response, tracking outcomes across a 44-week maintenance period.
Results from the maintenance study demonstrated clinically significant sustained efficacy in both indications. Remission rates reached 47-58% in ulcerative colitis patients, while endoscopic response rates of 41-55% were observed in Crohn's disease patients. The treatment demonstrated a consistent safety profile aligned with data from preceding clinical phases, with no new safety signals identified during the extended observation period.
Based on these maintenance study results, the companies are moving duvakitug forward into Phase III development. The advancement follows the drug's earlier demonstration of efficacy in induction therapy and reinforces the potential of TL1A antagonism as a therapeutic approach in inflammatory bowel disease management.